ArticleFrontiers in cardiovascular medicine2023
Association between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in hospitalised patients with COVID-19.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the intersection of sudden cardiac death and COVID-19: a comprehensive bibliometric analysis (2020-2024).Frontiers in cardiovascular medicine · 2024Pooled it
- Valvular Heart Disease and Heart Failure in the Post-COVID-19 Era: A Narrative Review of Mechanisms, Diagnosis, Differential Assessment, and Clinical Outcomes.Journal of clinical medicine · 2026Review
- The 3C dataset: A comprehensive dataset for COVID-19 cardiac complications diagnosis.Data in brief · 2026Article
- Machine learning-based risk prediction of outcomes in patients hospitalized with COVID-19 in Australia: the AUS-COVID Score.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Article
- Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States.Infectious diseases and therapy · 2025Article
- Patient physical condition and functional sequelae following hospitalization with COVID-19: A cross-sectional observational study.Medicine · 2025Observational
- Pandemics extend beyond infectious diseases: the emerging threat of non-communicable diseases.The Korean journal of internal medicine · 2025Article
- Cardiovascular presentations during the COVID-19 pandemic: an interrupted time series analysis.Journal of public health (Oxford, England) · 2025Article
- The impact of comorbidity on the quality of life of people who recovered from COVID-19 in Bangladesh.IJID regions · 2024Article
- Was there a weekend effect on mortality rates for hospitalized patients with COVID-19 and acute myocardial infarction? Insights from the National Inpatient Sample, 2020.Journal of medicine and life · 2024Article
- The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era.Journal of lipid and atherosclerosis · 2024Review
- Occult myocardial injury is prevalent amongst elderly patients in the hospital-at-home setting. A retrospective analysis of 213 patients.International journal of cardiology. Cardiovascular risk and prevention · 2023Article
- The Effect of Glycemic Control on Morbidity and Mortality in Critically Ill COVID-19 Patients.Cureus · 2023Article
- The Indirect Impact of COVID-19 Pandemic on Lower Extremity Amputations - An Australian Study [Letter].Vascular health and risk management · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pre-existing cardiovascular disease and cardiovascular risk factors are common in patients with COVID-19 and there remain concerns for poorer in-hospital outcomes in this cohort. We aimed to analyse the relationship between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in patients hospitalised with COVID-19 in a prospective, multicentre observational study. Method: This prospective, multicentre observational study included consecutive patients of age ≥18 in their index hospitalisation with laboratory-proven COVID-19 in Australia. Patients with suspected but not laboratory-proven COVID-19 and patients with no available past medical history were excluded. The primary exposure was pre-existing cardiovascular disease, defined as a composite of coronary artery disease, heart failure or cardiomyopathy, atrial fibrillation or flutter, severe valvular disease, peripheral arterial disease and stroke or transient ischaemic attack. The primary outcome was in-hospital mortality. Secondary outcomes were clinical cardiovascular complications (new onset atrial fibrillation or flutter, high-grade atrioventricular block, sustained ventricular tachycardia, new heart failure or cardiomyopathy, pericarditis, myocarditis or myopericarditis, pulmonary embolism and cardiac arrest) and myocardial injury. Results: 1,567 patients (mean age 60.7 (±20.5) years and 837 (53.4%) male) were included. Overall, 398 (25.4%) patients had pre-existing cardiovascular disease, 176 patients (11.2%) died, 75 (5.7%) had clinical cardiovascular complications and 345 (37.8%) had myocardial injury. Patients with pre-existing cardiovascular disease had significantly increased in-hospital mortality (aOR: 1.76 95% CI: 1.21-2.55, Conclusions: Pre-existing cardiovascular disease is associated with significantly higher mortality in patients hospitalised with COVID-19. This relationship may be partly explained by increased risk of myocardial injury among patients with pre-existing cardiovascular disease which in turn is a marker associated with higher mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.